Sign inJoin waitlistJoin the waitlist

SD

Shaker Dakhil

Clinical Professor · University of Kansas School of Medicine

Credentials: · · · ·

History

University of Kansas School of Medicine
Present

University of Michigan Health-Ann Arbor
1978–1980
Wayne State University
1975–1978
St. Joseph University School of Medicine-Lebanon
1971–1975

Research

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
New England Journal of Medicine · 2005 · 4,152 citations
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Journal of Clinical Oncology · 2008 · 1,381 citations
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Journal of Clinical Oncology · 2006 · 1,133 citations

CL
Charles Loprinzi
31 papers
Kendrith Rowland
19 papers
AJ
Aminah Jatoi
15 papers
JG
Julie Gralow
14 papers
PS
Philip Stella
13 papers
EP
Edith Perez
12 papers
Gabriel Hortobagyi
11 papers
SA
Steven Alberts
11 papers
JW
James Wade
9 papers
Kathy Albain
9 papers
Norman Wolmark
9 papers
PF
Patrick Flynn
9 papers

Grants

National Community Oncology Research Project
National Cancer Institute · UG1
Contact PI · $8.6M · Via Christi Regional Medical Center
2014–2020
Community Clinical Oncology Program
National Cancer Institute · U10
Contact PI · $23.1M · Via Christi Regional Medical Center
1983–2015

Clinical trials

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2030
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Site PI · Recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2020–2026
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Site PI · Unknown · Phase 3
Gynecologic Oncology Group
2012